Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

The most prevalent chronic neurodegenerative illness in the world is Alzheimer’s disease (AD). It results in mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial and psychological impact on the relatives of the patients. The review discusses...

Full description

Saved in:

Bibliographic Details
Main Authors:	Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, Dania Thaher, Weam Jaghama, Donia Karaman, Rafik Karaman
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Series:	Molecules
Subjects:	anti-amyloid drugs aducanumab lecanemab Alzheimer’s disease chaperones DMT
Online Access:	https://www.mdpi.com/1420-3049/29/21/5131
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease
by: Xiaoming Qi, et al.
Published: (2024-11-01)

Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
by: Byeong-Hyeon Kim, et al.
Published: (2025-01-01)

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve
by: Sarfaraz K. Niazi
Published: (2024-12-01)

Antibacterial Activity and Antifungal Activity of Monomeric Alkaloids
by: Amin Mahmood Thawabteh, et al.
Published: (2024-11-01)

Alzheimer's disease drug development pipeline: 2022
by: Jeffrey Cummings, et al.
Published: (2022-01-01)

Lecanemab’s Path Forward: Navigating the Future of Alzheimer’s Treatment in Europe Amidst the EMA's Rejection
by: Alessandro Martorana, et al.
Published: (2024-11-01)

Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
by: Pranay Sinha, et al.
Published: (2022-01-01)

Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®)
by: Adrianna Muciek, et al.
Published: (2024-12-01)

Dancing through neurocognitive changes: dance/movement therapy supporting caregivers and people living with Alzheimer's and other dementias
by: Cecilia Fontanesi, et al.
Published: (2024-12-01)

Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
by: Eliasz Engelhardt, et al.
Published: (2024-12-01)

Diagnosis and Treatment of Alzheimer’s Disease: Current Update
by: Younghee Yim, et al.
Published: (2025-01-01)

Amyloid-β Peptide-targeting Immunotherapy in Alzheimer Disease: A Systematic Review of Clinical Studies
by: Haideh Mosleh, et al.
Published: (2024-10-01)

Pathways to Alzheimer’s Disease: The Intersecting Roles of Clusterin and Apolipoprotein E in Amyloid-β Regulation and Neuronal Health
by: Alexandru Laslo, et al.
Published: (2024-10-01)

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
by: Linda J. Van Eldik, et al.
Published: (2024-10-01)

The effects of a bioavailable curcumin formulation on Alzheimer's disease pathologies: A potential risk for neuroinflammation
by: Shaun Cade, et al.
Published: (2024-12-01)

Biofluid biomarkers for Alzheimer’s disease: past, present, and future
by: An Chengyu, et al.
Published: (2024-12-01)

Relationship of fasting glucose and longitudinal Alzheimer's disease imaging markers
by: Robyn A. Honea, et al.
Published: (2022-01-01)

Neuroprotective role of epigallocatechin-3-gallate, albeginin and melanoxetin in alzheimer's disease
by: Arif Malik, et al.
Published: (2025-02-01)

GABA Signaling in Spatial Memory changes in Animal Model of Alzheimer’s disease
by: Bahareh Tavakoli-Far, et al.
Published: (2024-08-01)

Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review
by: Cyrus Jalili, et al.
Published: (2023-05-01)

Use of anti-amyloid therapies for Alzheimer’s disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology
by: Breno José Alencar Pires Barbosa, et al.
Published: (2024-11-01)

Amyloid-β and heart failure in Alzheimer’s disease: the new vistas
by: Hayder M. Al-Kuraishy, et al.
Published: (2025-02-01)

The Role of CSF Biomarkers in Discriminating Between Cerebral Amyloid Angiopathy and Alzheimer’s Disease Patients: Systematic Review of Clinical Studies
by: Zahra Razmkhah, et al.
Published: (2024-10-01)

Using cerebrospinal fluid biomarkers to diagnose Alzheimer’s disease: an Australian perspective
by: Dhamidhu Eratne, et al.
Published: (2024-12-01)

Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge
by: Shahram Darabi, et al.
Published: (2025-06-01)

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
by: Clifford R. Jack, et al.
Published: (2024-10-01)

Neuroprotective effect of ranolazine in mice's model of Alzheimer's disease
by: Mariam H. Sadiq, et al.
Published: (2024-06-01)

APOE from astrocytes restores Alzheimer’s Aβ-pathology and DAM-like responses in APOE deficient microglia
by: Pranav Preman, et al.
Published: (2024-11-01)

Novel targets for the treatment and prevention of Alzheimer's disease in the European population, inspiration from amyloid beta and tau protein
by: Xifeng Wang, et al.
Published: (2024-10-01)

Distinct Chemical Determinants are Essential for Achieving Ligands for Superior Optical Detection of Specific Amyloid‐β Deposits in Alzheimer's Disease
by: Dr. Xiongyu Wu, et al.
Published: (2024-12-01)

Deciphering the Role of Adrenergic Receptors in Alzheimer’s Disease: Paving the Way for Innovative Therapies
by: Androulla N. Miliotou, et al.
Published: (2025-01-01)

Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites
by: Felix S. Meier‐Stephenson, et al.
Published: (2022-01-01)

Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
by: Jimin Kim, et al.
Published: (2025-01-01)

Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
by: Fardin Nabizadeh, et al.
Published: (2024-07-01)

REELIN ameliorates Alzheimer's disease, but how?
by: Yu Katsuyama, et al.
Published: (2024-11-01)

In search of Alzheimer’s disease treatment methods: trends of clinical trials
by: G. Pakulaitė, et al.
Published: (2018-03-01)

Free water derived by multi‐shell diffusion MRI reflects tau/neuroinflammatory pathology in Alzheimer's disease
by: Moto Nakaya, et al.
Published: (2022-01-01)

Structural Analysis of Amylin and Amyloid β Peptide Signaling in Alzheimer’s Disease
by: Longsheng Xie, et al.
Published: (2025-01-01)

Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease
by: Zahra Farajzadeh Vahid, et al.
Published: (2024-12-01)

Advances in Alzheimer’s disease therapeutics: biochemistry, exploring bioactive compounds and novel approaches
by: Ayomide Victor Atoki, et al.
Published: (2023-09-01)